Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases. Shares of Adaptive were up over ...
Under the TCR-antigen data licensing agreement, Adaptive will receive an upfront payment and additional future potential annual licensing fees under this non-exclusive, multi-year data access ...
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases. Adaptive said it will earn up ...
Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the ...
FILE – Ryan Dutton, an EMT from Rescue Inc., prepares shots of the Pfizer COVID-19 booster vaccine during a vaccine clinic held by Rescue Inc. at Leland & Gray Middle and High School, in Townshend, Vt ...
Pfizer vaccine fails to provide expected immunity for kids ages 2-5 in trials; Extra dose now tested
Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.
Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...
SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback